Background Women experience adverse drug reactions, ADRs, nearly twice as often as
men, yet the role of sex as a biological factor in the generation of ADRs is poorly understood …

The Food and Drug Administration (FDA) reviewed 300 new drug applications between
1995 and 2000. Of the 163 that included a sex analysis, 11 drugs showed a> 40% difference …

This review summarizes gender differences (GDs) in drug response. Although GDs have
been described both in pharmacodynamics and pharmacokinetics, their role in clinical …

Women experience more adverse reactions to treatment with therapeutic drugs than men.
Theories proposed to explain this include overdosing, different pharmacokinetics and …

Significant differences that exist between the sexes affect the prevalence, incidence and
severity of a broad range of diseases and conditions. Men and women also differ in their …

Background Several publications indicate that the female gender experiences a higher
incidence of adverse drug reactions (ADRs) than does the male gender. The reasons …

Physiological, hormonal, and genetic differences between males and females affect the
prevalence, incidence, and severity of diseases and responses to therapy. Understanding …

Clinically relevant adverse drug reactions differ between men and women. The underlying
physiological and pharmacological processes contributing to these differences are …

Clinical data suggest that gender dimorphic profiles are emerging in terms of both drug
efficacy and adverse drug reactions (ADRs). With an increasing emphasis on individualised …

Pharmacological response depends on multiple factors and one of them is sex–gender.
Data on the specific effects of sex–gender on pharmacokinetics, as well as the safety and …